GlycanAge and Circulate Health announced the publication of a preprint that integrates IgG N-glycome data from 20,405 individuals across 42 independent studies processed between 2008 and 2025.
Led by Professor Gordan Lauc with coauthors from the Buck Institute, the University of Freiburg, King’s College London and other institutions, the analysis, according to the company, finds the IgG glycome independently predicts all-cause mortality and is responsive to intervention.
The study evaluated three geroprotective approaches — therapeutic plasma exchange, hormone replacement therapy and caloric restriction — and reports that therapeutic plasma exchange produced the largest per-month reduction in glycan age at -0.4 years per month. The company claims the work meets the Biomarkers of Aging Consortium criteria for a valid aging biomarker and positions the IgG glycome as both a mechanistic and predictive marker.
The release also cites earlier randomized evidence from Circulate showing that biweekly TPE, combined with intravenous immunoglobulin, reduced biological age by an average of 2.6 years across a multi-omics panel. The preprint frames glycan patterns as a link among chronic inflammation, disease risk and intervention responsiveness, according to the company.
